Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03996863 (PUCE Study), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PUCE Study: Prevention of Unmitigated Chemotherapy-induced Emesis
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Olanzapine for chemotherapy-induced nausea and vomiting in breast cancer: a systematic review and meta-analysis of prospective randomised controlled trials.European journal of clinical pharmacology · 2026Pooled it
- Trial
- Effects of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: a preliminary randomized controlled trial.BMC complementary medicine and therapies · 2022Trial
- Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study.Journal of pharmaceutical health care and sciences · 2026Article
- Incidence and Risk Factors of Delayed Chemotherapy-Induced Nausea and Vomiting Among Adult Patients: A Cross-Sectional Study.Nursing open · 2026Review
- Incidence and Risk Factors of Chemotherapy-Induced Nausea and Vomiting Among Adult Cancer Patients at Mbarara Regional Referral Hospital: A Prospective Study.Clinical pharmacology : advances and applications · 2026Article
- Assessment of nutritional status of patients receiving chemotherapy: sample from European Gaza hospital.BMC cancer · 2025Article
- LyeTxI-b, a Synthetic Peptide Derived From a Spider Venom, Is Highly Active in Triple-Negative Breast Cancer Cells and Acts Synergistically With Cisplatin.Frontiers in molecular biosciences · 2022Article
- Psychological predictors of chemotherapy-induced nausea in women with breast cancer: Expectancies and perceived susceptibility.European journal of cancer care · 2021Article
- Article
- Type A Trichothecene Diacetoxyscirpenol-Induced Emesis Corresponds to Secretion of Peptide YY and Serotonin in Mink.Toxins · 2020Article
- The incidence of nausea and vomiting in cancer patients in Greek clinical practice: A longitudinal study.Contemporary oncology (Poznan, Poland) · 2020Article
- A combination of Citrus reticulata peel and black tea inhibits migration and invasion of liver cancer via PI3K/AKT and MMPs signaling pathway.Molecular biology reports · 2020Article
- Granulin A Synergizes with Cisplatin to Inhibit the Growth of Human Hepatocellular Carcinoma.International journal of molecular sciences · 2018Article
- Single nucleotide polymorphisms might influence chemotherapy induced nausea in women with breast cancer.Clinical and translational radiation oncology · 2017Article
- Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management.Frontiers in pharmacology · 2017Review
- Intracellular vomit signals and cascades downstream of emetic receptors: Evidence from the least shrew (Remedy open access · 2017Article
- Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis.Therapeutic advances in medical oncology · 2016Review
- Impact of Chemotherapy on Diet and Nutritional Status of Women with Breast Cancer: A Prospective Study.PloS one · 2016Article
- Multiple Gastrointestinal Symptoms Are Associated With Chemotherapy-Induced Nausea in Patients With Breast Cancer.Cancer nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite newer agents, chemotherapy-induced nausea and vomiting (CINV) continues to remain a distressing side effect to a proportion of patients undergoing systemic anti-cancer therapy.
methodsWe recently performed an unplanned secondary analysis on a previously reported negative phase III trial (N08C3) looking at the efficacy of gabapentin/placebo in combination with dexamethasone and a 5HT3 receptor antagonist in the prevention of CINV for 413 patients undergoing regimens with highly emetogenic chemotherapy (HEC). In the current study, we attempted to better understand the higher than expected rate of overall patient satisfaction, despite a low complete response rate in both arms. Additionally, we looked at patient variables and their relationship to rates of CINV.
resultsApproximately one third of patients experienced more than mild nausea and reported scores on the Functional Living Index-Emesis that indicated interference with activities. Thirty-five percent reported nausea greater than 2.5 on a scale of 0 to 10 (0 being none), 19 % reported at least one emetic episode, and 49 % reported taking rescue medication. Nausea and vomiting on day 1, cisplatin therapy, and history of motion sickness significantly predicted delayed CINV. Age, combination chemotherapy (HEC with moderately emetogenic), and getting treatment for breast cancer predicted CINV on day 1. DISCUSSION: These data confirm previous reports that subgroups of patients may be more prone to acute and delayed CINV. Future CINV study design may benefit from a more individualized approach to CINV management, targeting those patients who are truly at risk for CINV despite continued drug development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.